Message from Leadership
FY 2021 is marked by notable progress and a momentous first for GHIT, despite the continuing Covid-19 pandemic. First, we want to begin with gratitude – to our development partners for their creativity, collaboration, and perseverance; to our longstanding and new funders and sponsors for their unwavering support and partnership; and to the global health community for its unity and innovation as we continue the fight against neglected diseases.
A watershed moment in GHIT's R&D history
In November 2021, the GHIT-invested Pediatric Praziquantel Consortium, a public-private partnership dedicated to the development of arpraziquantel celebrating its 10th anniversary, announced the completion of its pivotal Phase III trial in Côte d'Ivoire and Kenya for a new treatment option for schistosomiasis in preschool-aged children. The successful joint development of pediatric praziquantel represents one of GHIT's most significant R&D achievements to date. The new formulation and treatment option will bring hope and health to more than 50 million preschool-aged children in the coming years. The Covid-19 pandemic made a significant logistical impact on clinical programs; nevertheless, we remain firmly invested in meeting our original clinical targets, together with our partners, by the end of March 2023.
Vision for the GHIT 3.0
GHIT has initiated dialogue with our funders for our replenishment and solidified our investment strategy for GHIT 3.0 (FY 2023-2027), which we will announce later this fiscal year. We look forward to further collaboration with all stakeholders in coming years.
Osamu Kunii, MD, MPH, PhDGHIT Fund CEO
Hiroki Nakatani, MD, PhD, MHPEdChair & Representative Director